<DOC>
	<DOCNO>NCT01241461</DOCNO>
	<brief_summary>The purpose study assess safety tolerability LY2584702 Japanese patient advance and/or metastatic solid tumor proven effective therapy exists .</brief_summary>
	<brief_title>A Study LY2584702 Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Have histological cytological evidence diagnosis advance and/or metastatic cancer ( solid tumor ) refractory standard therapy and/or therapy know provide clinical benefit , standard therapy exists . Have presence disease amenable efficacy assessment define Response Evaluation Criteria In Solid Tumors ( RECIST ) . Japanese patient advance nonmeasurable disease elevation validate tumor marker may eligible , discuss agree upon investigator Lilly . Have adequate organ function include : Hematologic : Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , platelet great equal 100 x 109/L , hemoglobin great equal 9 g/dL ( transfusion allow prior enrollment within 2 week ) . Hepatic : Bilirubin le equal 1.5 time upper limit normal ( ULN ) , alkaline phosphatase ( ALP ) , alanine transaminase ( ALT ) aspartate transaminase ( AST ) less equal 2.5 time ULN , 5 time ULN patient hepatic metastasis . Patients bone metastasis may enter alkaline phosphatase value less 5 time ULN , long hepatic parameter meet inclusion criterion . Renal : Serum creatinine less equal 1.5 time ULN . Have performance status less equal 2 Eastern Cooperative Oncology Group scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy prior study enrollment recover acute effect therapy . Have estimate life expectancy 12 week great Are able swallow capsule Have receive treatment within 4 week initial dose study drug drug receive regulatory approval indication . Have serious preexist medical condition serious concomitant systemic disorder , opinion investigator , would preclude participation study . Prior clinical history tuberculosis ( patient doubt tuberculosis screening require ) , positive test result hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) ( screen require ) . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic patient without history CNS metastasis require . Have hematologic malignancy , lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>p70s6 inhibitor</keyword>
</DOC>